Cellbyte Raises $2.75M Seed to Accelerate AI-Powered Drug Launch Platform
Munich-based Cellbyte, an AI-native platform designed to help pharmaceutical companies accelerate and optimise the complex process of launching new drugs, has raised $2.75 million in seed funding to fuel its international expansion, product development, and team growth. The company, founded in 2024 by Daniel Moreira, Felix Steinbrenner, and Samuel Moreira, has rapidly gained traction in the pharmaceutical industry by offering technology that automates high-stakes pricing, market access, and regulatory workflows, enabling commercial teams to make faster, data-driven decisions when preparing drug launches.
The seed round was led by Frontline Ventures, a venture capital firm focused on backing ambitious B2B software companies across the US and Europe, with additional investors including Y Combinator, Pace Ventures, Saras Capital, and Springboard Health Angels. This mix of investors reflects confidence in Cellbyte’s vision and its potential to become an essential tool for pharmaceutical launches globally.
Cellbyte’s platform addresses one of the most burdensome challenges in the pharmaceutical commercial lifecycle — the volume and complexity of data that pricing, market access, health technology assessment (HTA), and regulatory teams must navigate when preparing a drug for launch. Traditional workflows often involve manually sifting through fragmented datasets from disparate sources, generating extensive documentation for regulatory approval, and modelling pricing and reimbursement strategies across multiple markets, which can take months or even years, delaying patient access to life-saving therapies. Cellbyte’s technology uses generative AI to analyse millions of data points in real time, producing reliable, high-quality insights that help teams prepare launch documents, identify optimal pricing strategies, and sequence go-to-market plans far more rapidly than legacy tools allow.
In its first months after launch, Cellbyte has experienced rapid growth, achieving six-figure annual recurring revenue within weeks and securing contracts with major global pharmaceutical companies, including Bayer. The company’s early performance reflects strong market demand for intelligent automation in drug launch planning, where reducing timelines and reliance on manual processes can translate into significant cost savings and competitive advantage. With the new funding, Cellbyte plans to triple its headcount, enhance its engineering and data capabilities, and deepen its international reach as it expands into key markets including the United States.
Frontline Ventures, as lead investor, cited the strength of the founding team’s vision and the platform’s potential to become an essential operating system for commercial pharmaceutical functions worldwide. Frontline’s partner William McQuillan highlighted that the technology addresses one of the industry’s most intractable bottlenecks — efficiently turning vast, fragmented datasets into actionable launch intelligence.
The participation of Y Combinator adds further validation, providing access to a broad network of mentors and potential partners, strengthening Cellbyte’s ability to scale and refine its product. The involvement of Pace Ventures, Saras Capital, and Springboard Health Angels complements that support with additional capital and sector-specific insights, particularly in early-stage tech and health innovation.
Cellbyte’s seed funding marks an important milestone not only for the company but also for the broader trend of applying generative AI to complex enterprise use cases. While AI has become ubiquitous in consumer applications, its integration into enterprise workflows — especially where high-stakes decision-making and regulated environments are involved — is still emerging. By providing a platform that blends advanced data integration, machine learning, and domain-specific workflows for pharmaceutical launches, Cellbyte is positioning itself at the forefront of this wave.
Looking ahead, Cellbyte aims to deepen its product capabilities, support a broader set of automated workflows tailored to diverse markets, and strengthen its organisational infrastructure to sustain rapid growth. With seed funding secured and early commercial success, the company is striving to become the go-to operating platform for pricing, market access, and regulatory teams globally, helping bring critical medicines to patients faster and with greater certainty than ever before.
